ICON is a contract research organization that manages clinical trials for pharmaceutical, biotechnology, and medical device companies. ICON handles all phases of clinical development, from early safety testing through post-approval studies. The company’s core offerings include full-service trial management, where ICON designs studies and recruits patients, and functional service provision, where ICON embeds staff into a client's own clinical operations. ICON also provides laboratory services and operates a global clinical research site network called Accellacare to support patient recruitment and retention. ICON earns revenue through long-term contracts consisting of direct service fees and pass-through costs for third-party expenses like investigator payments. ICON recognizes revenue as work is performed, and its business model depends on converting a contracted backlog into revenue. Because ICON’s cost base is predominantly labor, profitability is highly sensitive to employee utilization across active studies. ICON primarily serves large pharmaceutical firms through multi-year strategic partnerships and also targets biotechnology customers. Geographically, Europe is ICON's largest market, followed by the U.S. ICON's growth strategy focuses on deepening its large pharma partnerships, expanding in the biotech sector, and investing in AI technology to automate trial workflows.